
Wenzel Spine received FDA 510(k) clearance to market an expandable sacroiliac (SI) fusion implant, panaSIa. This milestone marks the first ever FDA clearance of an expandable SI fusion implant.
The system is available now through a limited commercial release, with full commercial availability 4Q25.
Available in two sizes to suit patient anatomy, panaSIa SI Fusion is designed for minimally invasive dorsal placement using streamlined instrumentation. Its expandable architecture allows the implant to pierce the ilium and sacrum, stabilizing the SI joint and enabling post-expansion graft delivery without disengaging the instrumentation.
“We are excited to bring this transformative innovation to market,” said William Wilson, CEO of Wenzel Spine. “FDA clearance for the panaSIa SI Fusion System reflects our continued commitment to improving patient outcomes through advanced, expandable technologies that meet the evolving needs of both surgeons and their patients.”
Source: Wenzel Spine, Inc.
Wenzel Spine received FDA 510(k) clearance to market an expandable sacroiliac (SI) fusion implant, panaSIa. This milestone marks the first ever FDA clearance of an expandable SI fusion implant.
The system is available now through a limited commercial release, with full commercial availability 4Q25.
Available in two sizes to suit patient...
Wenzel Spine received FDA 510(k) clearance to market an expandable sacroiliac (SI) fusion implant, panaSIa. This milestone marks the first ever FDA clearance of an expandable SI fusion implant.
The system is available now through a limited commercial release, with full commercial availability 4Q25.
Available in two sizes to suit patient anatomy, panaSIa SI Fusion is designed for minimally invasive dorsal placement using streamlined instrumentation. Its expandable architecture allows the implant to pierce the ilium and sacrum, stabilizing the SI joint and enabling post-expansion graft delivery without disengaging the instrumentation.
“We are excited to bring this transformative innovation to market,” said William Wilson, CEO of Wenzel Spine. “FDA clearance for the panaSIa SI Fusion System reflects our continued commitment to improving patient outcomes through advanced, expandable technologies that meet the evolving needs of both surgeons and their patients.”
Source: Wenzel Spine, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.